BOARD OF REGENTS



SUMMARY OF ITEM FOR ACTION INFORMATION OR DISCUSSION

TOPIC: BioHealth Innovation Maryland's Commercialization Collaborative					
COMMITTEE: Economic Development and Technology Commercialization					
DATE OF COMMITTEE MEETING: March 29, 2012					
SUMMARY: The Committee will be updated on the status of the Maryland BioHealth Innovation Initiative.					
ALTERNATIVE(S): This is an information item.					
FISCAL IMPACT: This is an information item.					
<u>CHANCELLOR'S RECOMMENDATION:</u> This is an information item.					
COMMITTEE RECOMMENDATION: DATE:					
BOARD ACTION: DATE:					
SUBMITTED BY: Joseph F. Vivona (301) 445-2783					



www.biohealthinnovation.org

"The Region"--Central Maryland

Unrivaled Research Assets Unfulfilled Commercial Promise




















The Problem--A National Challenge

America is falling behind the world it invented because we are:

- Out-educated
- Out-built in infrastructure
- Out-invested in R&D
 by countries in both Europe
 and Asia.
- -- "That Used to Be Us" by Thomas Friedman, 2011

The Reverse Brain Drain

- "Opportunities in China Lure Scientists Home" --The Washington Post, February 20, 2008
- American returnees to India cited as reasons for going "back" to where they came from:
 - better economic opportunities
 - family ties
 - better access to markets



National Leadership



President Obama's Bioeconomy Initiatives & America Invents Act (2011)

- America Invents Act
- Center for Advancing Translational Sciences in NIH to advance commercialization (NCATS)
- Develop a National Bioeconomy Blueprint by January 2012
- **Presidential Memo** "Accelerating Technology Transfer and Commercialization of Federal Research in Support of High-Growth Businesses"
 - Establish goals and measure progress
 - Streamline the federal government's technology transfer and commercialization process
 - Facilitate commercialization through local and regional partnerships



State Leadership



Maryland Governor O'Malley:

- BioMaryland 2020
- Invest Maryland
- Maryland Biotechnology Investment Tax Credit (\$6 m/yr)
- BioMaryland 2020 blueprint
- Invest Maryland (\$70 million)
- Maryland Life Sciences Advisory Board
- The Maryland Venture Fund
- Maryland Innovation Initiative



Challenges to Innovation Economy

Lack of connection of innovation resources

Lack of an entrepreneurial culture and C-level executives

Lack of early-stage funding for commercializing technologies

Lack of a STEM Workforce

BHI Value Proposition

Connects regional innovation assets

Develops an entrepreneurial talent and support pipeline

Attracts funding for technology commercialization

Develops a continuum of innovation workforce



BioHealth Regional Innovation Cluster Assets





































United States Army edical Research Institute















NCATS







What is A Regional Innovation Intermediary?


- An organization at the Center of the region's, state's and country's efforts
 - Align local technologies, assets and resources
 - Advance Innovation



- Regionally-oriented
- Private-public partnership,
 501(c)(3) nonprofit
- Market-driven, private sector-led
- Not a government initiative, nor a membership organization



BHI: An Innovation Intermediary that Connects Sectors, Industries, Communities, & Markets



Regional BioHealth Ecosystem Partners

ACADEMIA

- RESEARCH/T2
- LIFELONG LEARNING
- **ECONOMIC DEVELOPMENT**

INDUSTRY

- PROFIT
- PROCESS
- PRODUCT

INSEPARABLE MISSIONS

GOVERNMENT

- Sustainability
- INFRASTRUCTURE SUPPORT
 - ECONOMIC POLICY

FOUNDATIONS

- Economic Growth
- COMMUNITY INVESTMENT
- REGIONAL COLLABORATION



BHI Founding Partners and Sponsors

















BHI Funding Sources:

- private sector
- universities and foundations
- public sector













BHI Board of Directors

Michael J. Baader, Esq.

Managing Director, Venable LLP

Richard Bendis

Interim CEO, BioHealth Innovation, inc.

Scott Carmer (Chair)

Executive Vice President of Commercial Operations, MedImmune

Kenneth Carter

Chair, Noble Life Sciences

Ronald J. Daniels

President, Johns Hopkins University

David M. Gillece (Secretary)

Regional Managing Principal, Cassidy Turley

William E. Kirwan

Chancellor, University System of Maryland

Douglas Liu

Senior Vice President of Global Operations, Qiagen

David Mott

General Partner, New England Associates

Jerry Parrott

Vice President, Corporate Communications and Public Policy, Human Genome Sciences

William G. Robertson (Treasurer)

President & CEO, Adventist Healthcare

J. Thomas Sadowski


President & CEO, Economic Alliance of Greater Baltimore

Thomas Street

Assistant Chief Administrative Officer, Montgomery County Government



BHI Organizational Chart



BHI Industry Focus

- Biotechnology
- Medical Devices
- Healthcare Services
- E-Health
- Mobile Health
- Electronic Medical Records
- Health Informatics
- BioHealth Cyber Security







Innovation Paradigm Shift

PROOF OF CONCEPT
(Technological Feasibility)
Laboratory Push
"It Works!"



Maryland's Commercialization Collaborative




"It Works To Solve A Problem"
"I'll Buy It"





Innovation Capital "VALLEY OF DEATH"





Connect Funding Sources at Every Stage to Fill Gaps

DREAM	CONCEPT	APPLIED	COMMERCIAL RELEVANCE	STARTUP	ROLL OUT	GROWTH
FoundersFFF Bootstrapping Crowdfunding	Seed	Accelerator	IBED	Federal	ANGEL	VC
Friends Family SERIES CROWdfund WICKSTANTEN	NEA. INVEST MARYLAND	MHCPDC ECHCOUNC MdBio Md		Technology Innovation Program J.S. Small Business Administration USDA Rural Development	a	H. I. G. BIOVENTURES
RocketHub			18			

How does BHI work? Commercialization Pipeline

Sources and evaluates biohealth intellectual properties (IP)

Funds marketrelevant IP **Grows** and markets businesses and products





BHI Deal Goals

VC Regional History:

Last decade the region: *\$79.8 million per year** in biotechnology venture financing (2003-2010).



Goal:

150 prospective deals annually

Fund:

25% or 35 deals per year

Avg. Investment:

\$4.3 million per start-up

Targeted VC Annual Investment

\$150,000,000

*This includes an estimated \$57.7 million per year in Montgomery County, and \$22.1 million per year in the rest of the state.



Entrepreneur-in-Residence (EIR)

- A team leader who combines scientific, financial/VC and entrepreneurial management experience to:
 - Perform due diligence
 - Develop biohealth project-focused companies
- Proactively identifies and commercializes
 market-relevant intellectual properties from:
 - federal labs
 - universities
 - private sector



Partnership Intermediary Agreement (PIA)

- PIA between BHI and NIH's Office of Technology Transfer that supports the 27 NIH institutes' \$3 billion intramural research and the Food and Drug Administration.
- To promote and foster cooperative research and accelerate technology commercialization among NIH/FDA, businesses, and universities.







Innovation Resource Guide

"Financing and Entrepreneurial Resource for Montgomery County and the Greater Baltimore Region"

- Entrepreneur and Innovation Resource Network
- Innovator Financing Guide
- The Startup's Guide to Intellectual Property



BHI Road Map & H-RIC Implementation Strategy

Regional **Innovation** Commerciali-**Innovation Innovation Capital** zation & Jobs Workforce **Planning** University **BHI Direct Entrepreneurial Regional Cluster** &Federal Lab Investment Support Study Commercializatio **Program Programs** n Program **BioHealth Regional Angel** Innovation **INNoVATE Asset Mapping** Fund (\$5M) Acceleration program Start up/Mgt **Program** E-Health and M-SBIR/STTR Community Health Innovation Index **College Bio Assistance Competition &** Workforce Program Mgt. **Accelerator** Early-stage **Executive** in Entrepreneur's **Venture Fund** Residence **Resource Guide** (\$100M) Start **Programs** up/Mgt

Location & Infrastructure **Incubators &** Accelerators **Facility** Enhancement



BHI: Connecting Centers of Excellence in the Region

LifeSci Village™ at FDA



Great Seneca Science Corridor





Baltimore's Bayview Research Cluster



University of Maryland bioPark



Science + Technology Park at JHU



1st Year Action Items

- 1. Generate an initial 1st year financial commitment \$1.5M from public sector, academia, public foundations & industry.
- 2. Recruit Board Leadership, establish initial team & create a legal entity for BHI.
- 3. Develop specific metrics & outcome goals for BHI.
- 4. Source initial commercialization deal prospects locally, regionally, and globally.
- 5. Provide qualified candidate start-up firms with management counsel, business plan development support, network connection & access to early stage capital.
- 6. Create access to early stage capital through a network of existing funds & fund organizations.
- 7. Create an BHI early stage seed fund & angel fund.
- 8. Develop strategic partner relationships with existing regional organizations.
- 9. Apply for appropriate Global, Federal, Regional, State grant opportunities from Government, Foundation, & Industry sources.
- 10. Develop Strategic & operating plans for BHI.
- 11. Develop an electronic data base of all entrepreneurial, financial & innovation resources in the Region.



How is Success Measured? BHI Metrics – First 5 Years

	Now	In 5 Years
VC Funding for Biotech	\$79 Million	\$150
Gov't Funding for Biotech	Increased SBIR proposals & success	Improve Maryland's ranking
Source Prospective Deals Annually	30	150

Improve return on R&D investment by leveraging equity investment

Create and retain 1,300 jobs

Recruit entrepreneurs, experienced managers and businesses

Commercialize biohealth technologies and create biohealth companies



BHI: The Triple Bottom Line

Grows high-paying jobs and businesses

Expands tax base; improves economic vitality

...and Benefits human health!



BHI Contact

Rich Bendis Interim CEO

BioHealth Innovation, Inc.

111 Rockville Pike, Suite 800

215-593-3333

bendis@bendisig.com

www.biohealthinnovation.org

